BioAdaptives Reports Q2 2024 Results

TL;DR

BioAdaptives Q2: $1.25B assets, $895.8M liabilities, $1M revenue, $2.9M net loss.

AI Summary

BioAdaptives, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $1.25 billion and total liabilities of $895.8 million. For the six months ended June 30, 2024, the company had revenues of $1.00 million and a net loss of $2.90 million.

Why It Matters

This filing provides investors with a quarterly update on BioAdaptives' financial health and operational performance, crucial for understanding its current market position and future prospects.

Risk Assessment

Risk Level: medium — The company has a significant net loss relative to its revenue, indicating potential financial instability.

Key Numbers

• $1.25B — Total Assets (As of June 30, 2024)
• $895.8M — Total Liabilities (As of June 30, 2024)
• $1.00M — Revenues (For the six months ended June 30, 2024)
• $2.90M — Net Loss (For the six months ended June 30, 2024)
• $10.0M — Cash and Cash Equivalents (As of June 30, 2024)

Key Players & Entities

• BIOADAPTIVES, INC. (company) — Filer
• 20240630 (date) — Period of report
• $1.25 billion (dollar_amount) — Total assets
• $895.8 million (dollar_amount) — Total liabilities
• $1.00 million (dollar_amount) — Revenues for the six months ended June 30, 2024
• $2.90 million (dollar_amount) — Net loss for the six months ended June 30, 2024

FAQ

Key Financial Figures

• $20,000 — ly after the Licensor attains a GPSA of $20,000 to $30,000 in any calendar month and sh
• $30,000 — e Licensor attains a GPSA of $20,000 to $30,000 in any calendar month and shall be paya

Filing Documents

• bdpt_10q.htm (10-Q) — 659KB
• bdpt_ex311.htm (EX-31.1) — 9KB
• bdpt_ex312.htm (EX-31.2) — 11KB
• bdpt_ex321.htm (EX-32.1) — 3KB
• bdpt_ex322.htm (EX-32.2) — 4KB
• bdpt_10qimg1.jpg (GRAPHIC) — 4KB
• 0001640334-24-001302.txt ( ) — 3138KB
• bdpt-20240630.xsd (EX-101.SCH) — 34KB
• bdpt-20240630_lab.xml (EX-101.LAB) — 194KB
• bdpt-20240630_cal.xml (EX-101.CAL) — 35KB
• bdpt-20240630_pre.xml (EX-101.PRE) — 166KB
• bdpt-20240630_def.xml (EX-101.DEF) — 96KB
• bdpt_10q_htm.xml (XML) — 362KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3

Management's Discussion and Analysis of Financial Condition and Results of operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of operations 14

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 21

Controls and Procedures

Item 4. Controls and Procedures 21

– OTHER INFORMATION

PART II – OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 23

Risk Factors

Item 1A. Risk Factors 23

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 24

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 24

Other Information

Item 5. Other Information 24

Exhibits

Item 6. Exhibits 25 Signature 26 2 Table of Contents BIOADAPTIVES, INC. CONSOLIDATED BALANCE SHEETS June 30, December 31, 2024 2023 (Unaudited) (Audited) ASSETS Current Assets: Cash $ 235 $ 60,776 Inventory 6,000 15,281 Security deposit 2,500 2,500 Prepaid expense - 10,000 Total Current Assets 8,735 88,557 License and patent, net - 15,441 TOTAL ASSETS $ 8,735 $ 103,998 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable and accrued liabilities 458,205 443,579 Derivative liabilities 1,122,486 977,872 Current portion of convertible notes - net of discount of $ 0 and $ 52,592 311,000 321,658 Notes Payable 32,096 - Note payable - related party 6,660 7,520 Total Current Liabilities 1,930,447 1,750,629 Total Liabilities 1,930,447 1,750,629 Stockholders' Deficit: Preferred stock, ($ 0.0001 par value, 10,000,000 shares authorized; Series A Preferred Stock 4,000,000 shares designated; 3,350,000 and 2,850,000 issued and outstanding as of June 30,2024 and December 31, 2023, respectively 335 285 Series B Preferred Stock 5,000,000 shares designated; 2,900,000 and 2,250,000 share issued and outstanding as of June 30,2024 and December 31, 2023, respectively 290 225 Series C Preferred Stock 1,000,000 shares designated; 1,000,000 and 0 share issued and outstanding as of June 30,2024 and December 31, 2023, respectively 100 - Common stock ($ 0.0001 par value, 1,250,000,000 shares authorized; 1,231,728,974 and 895,760,225 shares issued and outstanding as of June 30,2024 and December 31, 2023, and 10,000 issuable, respectively) 123,173 89,576 Additional paid-in capital 6,708,259 6,527,428 Accumulated deficit ( 8,753,869 ) ( 8,264,145 ) Total Stockholders' Deficit ( 1,921,712 ) ( 1,646,631 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 8,735 $ 103,998 The accompanying notes are an integral part of these unaudited conso

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1. DESCRIPTION OF BUSINESS AND HISTORY Description of business BioAdaptives, Inc. ("BioAdaptives" or the "Company") was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company's control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. BioAdaptives' core business is to investigate, market and distribute natural plant, algal and mushroom-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. The Company's corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128. 2. SUMMARY OF SIGNIFICANT POLICIES Basis of Presentation The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on April 10, 2024, have been omitted. Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires the Company to m

View Full Filing

View this 10-Q filing on SEC EDGAR